REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

The second episode of The Leaders’ Room season two features Regeneron Ireland lead, Muriel O’Byrne. The Leaders’ Room podcast features interviews with the country managers of some of Ireland ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

Regeneron beat Q4 estimates with $12.07 EPS and $3.79B in sales. The company announced a dividend, a $3 billion buyback, and continued R&D investments.

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company with a market capitalization of $59.31 million, has entered into a clinical supply agreement with Regeneron ...

Business activity in Northern Ireland has dropped for the first time in around a year with factors like the Holyhead port shutdown playing a part, a survey said today. According to the Ulster Bank ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... industries getting support from healthy economic activity and easier YoY comparisons. Furthermore, all 11 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today will share corporate progress and highlights from the Company’s broad and diverse investigational pipeline while presenting at the annual J.P ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Regeneron (REGN – Research Report), with a price target of $950.00. The company’s shares closed last ...